BofA Securities analyst Graham Perry upgraded GlaxoSmithKline (NYSE: GSK) from Underperform to Neutral.The analyst comments "We upgrade to Neutral and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE